We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 328

Court Can't Review Policy Behind Patent Term Adjustment Statute
  • Foley & Lardner LLP
  • USA
  • April 14 2016

In Singhal v. Lee, the U.S. District Court for the Eastern District of Virginia dismissed a complaint that challenged the Patent Term Adjustment


Methods Exploiting Junk DNA May Be Useful But Lack Patent Eligibility
  • Foley & Lardner LLP
  • USA
  • April 11 2016

Striking another blow against patent eligibility in the field of biotechnology, the Federal Circuit agreed with the district court that methods that


Will the Federal Circuit Invalidate 13,500 Continuation Patents?
  • Foley & Lardner LLP
  • USA
  • April 5 2016

The Federal Circuit is set to hear oral arguments in Immersion Corp. v. HTC Corp. on May 6, 2016. According to the amicus brief filed on behalf of


Patent Term Adjustment Versus Double Patenting
  • Foley & Lardner LLP
  • USA
  • February 25 2016

In Magna Electronics, Inc. v. TRW Automotive Holdings Corp., No. 1:12-cv-654; 1:13-cv-324 (Dec. 10, 2015), Judge Maloney of the U.S. District Court


Court cites objects of invention in claim construction
  • Foley & Lardner LLP
  • USA
  • February 24 2015

Pacing Technologies, LLC v. Garmin International, Inc. is one of those Federal Circuit decisions that may send patent practitioners running to their


Purdue OxyContin Patents Invalid Despite Stemming From Discovery Of Source Of Toxic Impurity
  • Foley & Lardner LLP
  • USA
  • February 2 2016

In Purdue Pharma L.P. v. Epic Pharma LLC, the Federal Circuit affirmed the district court decision holding four OxyContin patents invalid as obvious


District court finds Genetic Technologies patent invalid under 101 on motion to dismiss
  • Foley & Lardner LLP
  • USA
  • November 6 2014

Judge Stark of the U.S. District Court for the District of Delaware granted defendants' motion to dismiss Genetic Technologies, Ltd.'s patent


Losing Competing Property Not A Teaching Away
  • Foley & Lardner LLP
  • USA
  • January 12 2016

In In re Urbanski, the Federal Circuit upheld the decision of the USPTO Patent Trial and Appeal Board (PTAB) finding the claims of Urbanski's patent


Remicade Biosimilar Closer To Approval, But Patent Dance Goes On
  • Foley & Lardner LLP
  • USA
  • February 11 2016

Celltrion’s biosimilar version of Janssen’s Remicade (infliximab) product cleared a significant regulatory hurdle on February 9, 2016, when the Food


USPTO issues final Patent Term Adjustment rules under Novartis
  • Foley & Lardner LLP
  • USA
  • January 12 2015

The USPTO has published final Patent Term Adjustment (PTA) rules addressing the treatment of Requests for Continued Examination (RCEs) under the